Neurelis Files New Drug Application With The FDA For VALTOCO™ (Diazepam Nasal Spray), An Investigational Treatment For Pediatric, Adolescent And Adult Epilepsy Patients

SAN DIEGO, CA – Sept. 25, 2018 — Neurelis, Inc. today announced that the company has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for VALTOCOTM (diazepam nasal spray) as a treatment for epilepsy patients six years and older who experience increased bouts of seizure activity, also known as […]

You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.

Do you want to link to this third-party site and leave Neurelis.com?

You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.

Do you want to link to this third-party site and leave Neurelis.com?

You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.

Do you want to link to this third-party site and leave Neurelis.com?

You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.

Do you want to link to this third-party site and leave Neurelis.com?

You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.

Do you want to link to this third-party site and leave Neurelis.com?

You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.

Do you want to link to this third-party site and leave Neurelis.com?

You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.

Do you want to link to this third-party site and leave Neurelis.com?

You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.

Do you want to link to this third-party site and leave Neurelis.com?

You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.

Do you want to link to this third-party site and leave Neurelis.com?

You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.

Do you want to link to this third-party site and leave Neurelis.com?

You are about to enter a site containing information on Medical Affairs and Research that is intended for US healthcare professionals only. Please confirm you are a healthcare professional and you wish to proceed to the HCP-only site.